Bridgette P. Heller Sells 352 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette P. Heller sold 352 shares of DexCom stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $70.33, for a total value of $24,756.16. Following the completion of the sale, the director now directly owns 22,997 shares in the company, valued at approximately $1,617,379.01. This represents a 1.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

DexCom Trading Up 2.4 %

Shares of NASDAQ:DXCM opened at $75.11 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a market cap of $29.35 billion, a PE ratio of 52.52, a P/E/G ratio of 2.30 and a beta of 1.28. The business has a 50 day moving average of $83.41 and a 200-day moving average of $76.92. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Institutional Investors Weigh In On DexCom

Several institutional investors have recently made changes to their positions in DXCM. Jennison Associates LLC boosted its stake in shares of DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after buying an additional 6,544,102 shares during the period. Norges Bank bought a new stake in shares of DexCom in the fourth quarter valued at approximately $385,367,000. Congress Asset Management Co. boosted its stake in shares of DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after buying an additional 1,332,522 shares during the period. Fisher Funds Management LTD bought a new stake in DexCom during the fourth quarter worth $96,507,000. Finally, Westfield Capital Management Co. LP lifted its stake in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DXCM has been the topic of a number of recent research reports. Citigroup lifted their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.